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Abstract  
Background: Eugenia polyantha, Apium graveolens, 
and Nigella sativa are extracts which in preclinical trial 
can reduce uric acid serum, increase urinary uric acid 
excretion. Allopurinol is an inhibitor of the xanthine 
oxidase enzyme which can also reduce the increase of 
hsCRP in subjetcs with hyperuricemia. 
Objective: To determine the safety and effect of herbal 
extracts in reducing serum uric acid, increasing uric acid 
excretion and reducing hsCRP levels in patients with 
hyperuricemia compared with allopurinol. 
Method: This study was a double blind randomized 
controlled trial (RCT). The subjects were hyperuricemic 
patients aged ≥18 years. The subject was divided into 
groups that received 3000 mg/day of herbal extracts and 
allopurinol 100 mg/day for 4 weeks. Evaluation of serum 
uric acid and urinary uric acid urine were every week, and 
hsCRP levels was baseline and end of intervention. Other 
parameters related to the safety of use were examined 
every 2 weeks. 
Results: A number of 44 hyperucemia subjects, 
23 subjects received herbal extracts and 21 
subjects received allopurinol. The decrease of 
uric acid serum levels in the herbal extract group 
was 0,467±1,123;0,600;-2,70-3,00 (p=0.027), 
while in the allopurinol group 1,114±0,813;1,30;-
1,30-2,30 (p=0,000). Uric acid excretion in the 
herbal extract group decrease 71,00±1,970;5,50;-
92,00-702,00 (p=0,269) and in the allopurinol 
group decrease 64,54±1,298;22,00;-29,00-440,0 
(p=0.003). The reduction of hsCRP in the herbal 
extract group was 0.08±0.639; 0.01; -1.55-2.05 
(p=0.658), and the allopurinol group was -0.33 ± 
0.806; -0.01; -2.73- 0.31 (p=0.256).  
Conclusion: Herbal extracts (Eugenia poliantha, Apium 
graveolens and Nigella sativa) and allopurinol can reduce 
serum uric acid levels in patients with hyperuricemia. 
Allopurinol also can reduce urinary uric acid excretion. 
 
Introduction 
Hyperuricemia is a condition in which serum uric 
acid levels increase ≥ 7 mg / dl in men and ≥ 6 mg / 
dl in women. It is a risk factor for the onset 
 
 
of arthritis gout, gout or kidney stone nephropathy 
and the incidence of cardiovascular disease.1 The 
prevalence of hyperuricemia as reported in Bali in 
2010 about 14.5%.2 Allopurinol as a widely used as 
xanthine oxidase inhibitor has reported side effects 
5-10%.3  
Eugenia polyantha, Apium graveolen, and Nigella 
sativa are uric acid lowering extracts that have 
become standardized herbal medicines in Indonesia. 
In preclinical studies, the composition of herbal 
extracts that are effetive at reducing serum uric acid 
levels is at a dose of 30-40 mg. At a dose of 30 mg it 
consists of 13 mg (43.3%) bay leaf extract (Eugenia 
polyantha), 10 mg (33.3%) celery extract (Apium 
graveolens) and 7 mg (23,33%) black cumin seed 
extract (Nigella sativa).4 Eugenia polyantha contains 
0.2% essential oils, flavonoids (quercetin, quercitrin, 
myricitrin and myricetin) and tannins.5 Quercitrin and 
myricetin are the competitive inhibitors of the 
xanthine oxidase enzyme.6 The main content of Apium 
graveolen is flavonoids apigenin, inositol, asparagine, 
glutamine, choline and linamarosa.5 Flavonoids 
apigenin is a xanthine oxidase competitive inhibitor 
enzyme. Infuse 10% of Apium graveolen (5 ml/kg) 
can reduce uric acid levels as same as probenecid 20 
mg/kg and associated with increased uric acid 
excretion. Nigella sativa (black cumin) has been 
shown to increase urine volume and excretion of uric 
acid in urine in pre-clinical studies.8,9  
Eugenia polyantha (43.3%), Apium graveolen  
(33.3%) and Nigella sativa (23.33%) at doses of 
2000 mg/24 hours have been shown to reduce 
serum uric acid levels by 0,12±0.91 mg/dl (p <0.05) 
and increase urinary excretion of uric acid 1.78 ± 
390.83 mg/24 hours (p <0.05) at day 14th. 10  
C-reactive protein (CRP) is mostly synthesized in the 
liver. In the transcription phase is affected by 
proinflammatory cytokines. IL-6 being the main 
regulator supported by C/EBPβ and C/EBPγ is a key 
factor of transcription. In addition, IL-6 will provide a 
signal strengthened by IL-1β and TNFα in enhancing 
the transcription process of CRP.11 Increased 
expression of CRP in conditions of 
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uric acid levels >6mg/dl is caused by activation of p38 and 
ERK44/42 MAPK.12 The inflammatory process that occurs is 
caused by accumulation of monosodium urate (MSU) crystals 
caused by increasing serum uric acid levels. Monosodium urate 
binds to caspase I activating NALP3 inflammasone, resulting in 
the expression of IL-1β and IL-18.13 In another study it was also 
mentioned that MSU induces the release of TNF cytokines. 
Evidence in other studies also states that hyperuricemia is 
associated with hsCRP levels. 14  
The purpose of this study was to determine the effect of herbal 
extracts (Eugenia polyantha, Apium graveolens and Nigella 
sativa) on serum uric acid, uric acid and high sensitivity c-
reactive protein levels in patients with hyperuricemia and the 
safety of herbal extracts compared with allopurinol. 
 
Method 
This study is a double blind randomized controlled trial. Subjects 
were hyperuricemic patients with inclusion criteria aged> 18 
years with blood uric acid levels> 7 mg/dl (male) and > 6 mg/dl 
(female) and willing to take drugs given with exclusion criteria 
for liver function disorders with AST >40 U/L; and or ALT >65 
U/L; impaired kidney function with creatinine > 1.5 mg/dl or 
ureum >40 mg/dl; malignancy; use of drugs that affect uric acid 
levels such as diuretics, pyrazinamides, and salicylic acid; 
chronic inflammation (RA, IBD); attacks of acute gout; 
hypersensitivity to allopurinol and use of anti-inflammatory 
drugs: NSAIDs, steroids and  
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colchicine for the hsCRP variable.  
Screening is done to get prospective subjects who meet the 
inclusion criteria. Subjects who had used gout-lowering drugs, 
washed out 2 weeks before screening. The samples were 
randomly divided into 2 groups, group X was the group that 
received herbal extracts 3 x 2 capsules (@ 500mg) in a day for 
28 days, group Y was the group that received allopurinol 3 x 
2 capsules (100 mg) in a day for 28 days. Both groups received 
nutritional education according to the nutrition guide for 
patients with hyperuricemia from the nutrition department of 
Kariadi Hospital.  
On day 0, day 7, day 14, day 21 and day 28, samples were 
taken for examination of serum uric acid, urinary uric acid and 
history and physical examination related to complaint taking 
the drugs given. On day 0, 14 and 28, a routine blood test was 
carried out: hemoglobin, leukocytes, platelets, ureum, 
creatinine, AST, and ALT. Serum hsCRP levels were taken at 
day 0 and day 28. Data obtained were recorded in the subject’s 
developmental record. 
 
Results 
Based on the randomization of subjects divided into two 
groups, 23 subjects received herbal extracts therapy with a 
dose of 3 x 1000 mg and 21 people received allopurinol 
therapy with a dose of 1 x 100 mg allopurinol. The flowchart 
of the selection of research subjects is presented in Figure 1 
below. 
 
 
Screening was carried out for 304 people with  
risk factors for hyperuricemia  
 
 
62 candidate subjects corresponding to  
inclusion criteria 
 
 
 
 
44 subjects fulfilled the inclusion and  
exclusion criteria 
 
 
 
 
 
 
 
Exclusion:  
• 3 uses furosemide  
• 6 are unable to participate 
in further research  
• 3 liver function disorders  
• 5 kidney function disorders  
• 1 anemia 
 
Randomization 
 
 
 
 
 
 
  
recieved 
  
 23 subjects herbal extract  21 subjects allopurinol recieved 
     
      
 
Figure 1. Subjects Disposition 
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Table 1. Baseline characteristics of Randomized Subjects 
 
Characteristics 
Herbal Extracts Allopurinol  
p 
(n=23) 
 
(n=21) 
 
     
Age (years old) 46,8±12,60; 48,0; 26-65 49,5±13,04; 55,0; 26-65 0,439 a 
(mean±SD; median; min-max)      
Weight (kg) 73,4±15,83; 71,5; 50-110 74,2±14,89;76,0; 42-99 0,867 b 
(mean±SD; median; min-max)      
Gender, n (%)      
• Male 12 (52,1) 10 (47,6) 1,000 c 
• Female 11 (47,9) 11 (52,4)  
Obesity, n (%)      
• Obesity 14 (60,8%) 14 (66,7) 1,000 c 
• Non 9 (39,2%) 7 (33,3%)  
Diabetes History, n (%)      
• Diabetes  1 (4,4%) 4 (19,0%) 0,267 c 
• Non Diabetes 22 (95,6%) 17 (81,0%)  
Recent use of Allopurinol, n (%)      
• Yes 6 (26,1%) 5 (22,7%) 1,000c 
• No 17 (73,9%) 17 (77,3%)  
Hypertension, n (%)      
• Yes 7 (30,5%) 10 (47,6%) 0,267 c 
• No 16 (69,5%) 11 (52,4%)  
Hyperuricemia phase n (%) 
12 (52,1%) 9 (40,9%) 0,549 c • Hiperurisemia asimptomatik 
• Fase interkritikal 11 (47,9%) 13 (59,1%)  
Serum uric acid levels (mg/dl) 7,59±1,253; 7,25; 6,1-11,7 7,45±1,022; 7,40; 6,1-9,9 0,864a 
(mean±SD; median; min-max)      
Urinary uric acid levels (mg/dl) 121,71±1,906; 60,50;5,0-724,0 115,50±1,304; 65,10; 15,0-515,0 0,211a 
(mean±SD; median; min-max)      
HsCRP leves (mg/dl) 0,63±0,62; 0,46; 0,08-2,38 0,39±0,31; 0,30; 0,01-3,00 0,379a 
(mean±SD; median; min-max)      
      
aMann-Whitney test b t-independent test c Chi-square test     
 
Table 2. Comparison of Serum Uric Acid Levels in Both Treatment Groups  
 
 Herbal Extracts Allopurinol 
p  
(n=23) (n=21)   
    
Week 0 7,59±1,253; 7,25; 6,1-11,7 7,45±1,022; 7,40; 6,1-9,9 0,864a 
Week 1 7,51±1,358; 7,05; 6,0-10,5 6,79±1,878; 6,50; 4,4-11,1 0,080a 
Week 2 7,75±1,258; 6,90; 5,7-10,4 6,60±1,578; 6,60; 4,3-10,4 0,078a 
Week 3 7,28±1,464; 6,90; 3,9-10,5 6,33±1,444; 6,10; 3,9-10,1 0,040b 
Week 4 7,13±1,313; 6,95; 4,7-10,5 6,33±1,580; 6,20; 4,0-11,2 0,016a 
    
aMann-Whitney test b T-independent test   
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Figure 2. Graphic of Serum Uric Acid Levels in Both Treatment Groups 
 
Serial analysis (Friedman’s test) in both groups showed that there was a significant (significant) decrease in 
serum uric acid levels 0 to 4 weeks, both in the herbal extracts group (p = 0.026) and allopurinol group (p = 
0.000) (Figure 2). The median value for the allopurinol group was lower than herbal extracts starting from the 1st 
week to the 4th week. 
 
Table 3. Comparison of Decreased Serum Uric Acid Level in Both Treatment Groups   
 Herbal Extracts Allopurinol 
p  
(n=23) (n=21)   
    
Week 0 and 1 0,075±0,786; 0,10;-2,75-1,40 0,6619±1,253; 0,90; -3,10-2,00 0,007a 
Week 0 and 2 0,316±1,220; 0,25; -2,2-4,1 0,847±0,888;1,00;-0,70-2,30 0,032a 
Week 0 and 3 0,333±1,142;0,40;-2,70-2,70 1,114±0,824;1,142;-0,70-2,40 0,013b 
Week 0 and 4 0,467±1,123;0,600;-2,70-3,00 1,114±0,813;1,30;-1,30-2,30 0,018a 
    
 
aMann-Whitney test b T-independent test    
Table 4 Crosstabulation of Treatment Group for decreased serum uric acid levels 
    
  Herbal Extracts Allopurinol 
  N (%) N (%) 
Serum Uric Acid Levels Not decrease 8 (53) 1 (5) 
 Decrease 15(47) 20 (95) 
Total  23 21 
   P = 0,023 
 
Table 5 Crosstabulation of Treatment Group for targeted serum uric acid level (<6 mg / dl)  
 Herbal Extracts Allopurinol 
 N (%) N (%) 
Not reaching the target 20 (87) 14 (67) 
Serum Uric Acid Levels   
Reaching the target 3 (13) 7 (33) 
Total 23 21 
  P=0,155 
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COMPARISON OF URINARY URIC ACID LEVELS 
 
Table 6. Comparison of urinary uric acid levels at week 0 to week 4 of the both treatment groups   
  Group p 
     
  Herbal Extracts Herbal Extracts  
  (n=23) (n=23)  
    
Week 0 121,71±1,906; 60,50;5,0-724,0 115,50±1,304; 65,10; 15,0-515,0 0,211a 
Week 1 71,08±92,273; 52,50; 5,0-481,0 54,50±36,129; 54,0; 7,0-168,0 0,750a 
Week 2 59,93±30,591; 75,00;13,0-108,0 57,76±30,990; 58,0; 6,0-125,0 0,577a 
Week 3 58,10±32.109; 49,50; 14,0-113,0 50,28±29,094; 52,00; 7,0-147,0 0,426a 
Week 4 50,708±31,170; 50,0; 10,0-117,0 50,95±18,540;53,0;11,0-79,0 0,975b 
    
aMann-Whitney test b T-independent test    
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Figure 3. Graphic of Urinary Uric Acid Excretion Levels in Both Treatment Groups 
 
In Figure 3 above shows that serial analysis of uric acid excretion in urine in the allopurinol group, there was a 
significant decrease between week 0 and week 4 (Friedman test, p =0.003), whereas in the herbal extracts group 
there was no significant difference (Friedman test, p = 0.269). The median uric acid level of the second week in 
the herbal extracts group was greater than in the allopurinol group, although statistically the difference was not 
significant (p> 0.05). 
 
Table 7. Comparison of decrease urinary Uric Acid levels of both treatment groups 
 
 Herbal Extracts Allopurinol p 
 (n=23) (n=21)  
Week 0 and 1 50,62±2,092 ; 9,0; -407,9-644,0 60,99±1,299;22,00;-44,00-454 0,127 
Week 0 and 2 61,77±1,923;-4,65;-54,00-690,00 57,73±1,280;19,00;-38,00-439,00 0,142 
Week 0 and 3 63,61±1,827; 0,85; -77,00-623,00 65,21±1,295;32,00;-83,00-455,00 0,054 
Week 0 and 4 71,00±1,970;5,50;-92,00-702,00 64,54±1,298;22,00;-29,00-440,0 0,183 
 
HsCRP levels in both groups did not differ either at week 0 (p = 0.379), week 4 (p = 0.267), and decrease levels of 
hsCRP at week 4 from week 0 (p = 0.295). In both groups, there was a decrease in HsCRP level 4 weeks from week 0 
(P herbal extract = 0.658 and p allopurinol = 0.256). However, the hsCRP level of the herbal extract group tended to 
decrease at 4 weeks (0.08  
± 0.639; 0.01; -1.55-2.05) and the allopurinol group tended to increase at the 4th week (-0.33 ± 0.806 ; -0.01; -
2,73-0,31). 
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Table 8. Comparison of HsCRP levels at week 0 and week 4 of Both Treatment Groups  
 Herbal Extracts Allopurinol P 
 (n=23) (n=21)  
Week 0 0,63±0,62; 0,46; 0,08-2,38 0,39±0,31; 0,30; 0,01-3,00 0,379a 
Week 4 0,55±0,917;0,70;-1,55-2,050 0,73±0,860;1,40;0,04-3,00 0,267a 
Decreases levels week 0 and 4 0,08±0,639;0,01;-1,55-2,05 -0,33±0,806;-0,01;-2,73-0,31   0,295a 
P Week 4th and 0th 0,658b 0,256b 
    
 
a Mann-Whitney test b Wilcoxon test  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Box Plots for decreasing hsCRP Levels in Both Treatment Groups 
 
The decrease in hsCRP levels in the week 4 in the herbal extract treatment group was 10 (52%) subjects compared 
to allopurinol treatment groups as much as 8 (47%), but the differences were not significant. 
 
SAFETY OF HERBAL EXTRACTS AND ALLOPURINOL  
During 4 weeks study several complaints were obtained, such as diarrhea 2-3 in 1 subject in the herbal 
extract group for 1 day in the first week. Nauseous complaints also appear in the allopurinol group, but 
subjects can still continue taking allopurinol. 
 
Table 9 Comparison of Laboratory Parameters of Side Effects 
 
Parameter  Herbal Extracts Allopurinol p 
  (n=23) (n=21)  
Hb (g/dl) Week 0 13,7±1,60;13,6;10,2-16,9 14,1±1,33;14,4;11,2-16,8 0,416* 
 Week 2 13,8±1,68;13,7;9,4-16,8 13,9±1,34;14,5;11,5-16,3 0,752* 
 Week 4 14,0±1,68;13,7;10,5-16,7 13,9±1,34;14,2;10,7-16,0 0,820* 
 p different weeks 0 and 4 0,207*** 0,143***  
Leukocytes Week 0 8,2±1,94;8,0;3,6-14,0 8,8±1,30;8,9;6,0-10,8 0,212* 
(103 cell/ Week 2 7,8±1,78;7,9;4,8-12,3 7,6±1,55;7,62;4,3-10,4 0,733** 
mm3) Week 4 7,8±2,12;7,1;4,7-12,8 7,8±1,45;7,9;5,1-11,5 0,664** 
 p different weeks 0 and 4 0,009**** 0,004*** ` 
Platelet Week 0 298±65,5; 287;186-432 313±65,3;302;206-436 0,444* 
(103 cell/ Week 2 289±51,3;286;195-406 304±71,3;3,22;180-440 0,434* 
mm3) Week 4 303±55,4;296;205-400 316±70,1;311;193-446 0,488* 
 p different weeks 0 and 4 0,331*** 0,568***  
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Parameter  Herbal Extracts Allopurinol p 
  (n=23) (n=21)  
AST Week 0 20±6,47;18;13-35 21,3±5,50;20;13-34 0,254** 
(U/l) Week 2 20,3±6,12;19,5;10-34 24,1±7,26;24;14-39 0,066* 
 Week 4 21,3±5,84;20,5;12-34 23,6±7,24;20;13-39 0,240* 
 p different weeks 0 and 4 0,300**** 0,037***  
ALT Week 0 24,8±1,40;18,5;10-65 26,1±1,06;24;10-55 0.305** 
(U/L) Week 2 23,2±1,27;20;10-60 28,4±1,28;28;10-59 0,130** 
 Week 4 24,0±1,26;19,5;11-51 28,42±1,37;27;7-53 0,275** 
 p different weeks 0 and 4 0,778**** 0,257***  
Ureum (mg/ Week 0 23,8±5,60;24,5;15-34 27,6±6,56;26;15-40 0,045* 
dl) Week 2 21,1±5,42;19,5;14-34 26,2±6,98;24;17-46 0,010** 
 Week 4 22,4±5,57;22,5;12-24 27,1±8,92;25;14-52 0,058** 
 p different weeks 0 and 4 0,195**** 0,674****  
Creatinine Week 0 0,93±0,196;0,96;0,59-1,27 0,97±0,188;0,95;0,57-1,27 0,491* 
(mg/dl) Week 2 0,91±0,207;0,91;0,52-1,27 0,94±0,271;0,95;0,40-1,60 0,690** 
 Week 4 0,90±0,178;0,90;0,60-1,16 0,92±0,183;0,93;0,56-1,30 0,640* 
 p different weeks 0 and 4 0,020*** 0,020***  
* T-independent test ** Mann-Whitney test *** T-paired test **** Wilcoxon test  
 
 
Side effects assessed in this study were routine blood count 
(Hemoglobin, Leukocytes and platelets), liver function (AST 
and ALT) and kidney function (urea and creatinine). Table 6 
shows that hemoglobin levels, platelet counts, ALT levels, and 
urea levels did not show significant differences at week 0 and 
week 4 in both treatment groups. The leukocyte count and 
creatinine level 0 and 4 weeks in both treatment groups 
decreased significantly. In the allopurinol group there was a 
significant increase in AST levels between baseline and week 
4 with a mean increase of 21.3 ± 5.50 to 23.6 ± 7.24 with p = 
0.037, while in the herbal exctract group it was not a 
significant increase occurred. The ureum level at week 0 and 
week 2 in the group had a significant difference, where the 
allopurinol group was higher than the herbal exctract group (p 
= 0.045 and p = 0.010). 
 
DISCUSSION  
Effects of herbal extracts and allopurinol on serum 
uric acid levels  
Administration of allopurinol 100 mg/24 hours for 4 weeks 
found a decrease in serum uric acid levels 1.29 ± 0.629 mg / 
dl, when compared to the study conducted by Scott et 
al.(1966) obtained a mean decrease in uric acid levels from 9.3 
to 5.8 mg / dl at the same dose as 2 weeks.15 In another study 
with 120 days of allopurinol with a mean dose of 261 mg / day 
it was found to decrease as much as 34% (from 10 to 6.6 mg / 
dl) .16  
In the group that received herbal extracts there was a decrease 
from day 0 to day 28 (week 4) with 0.47 ± 1.123, although 
compared to the group of allopurinol smaller (1.11  
± 0.813), but the decreased serum uric acid levels with a dose of 
3000 mg/day is greater than dose of 2000 mg/day (0.12 ±  
0.91). 4  
The Phase III febuxostat study comparing the effectiveness of 
febuxostat 80 mg/day, 120 mg/day, and 240 mg/day with 
allopurinol 300 mg/day for 28 weeks with the output of normal 
 
 
serum uric acid levels (< 6 mg/dl) was 76% (122/161), 87% 
(163/188), and 94% (78/83), while allopurinol 41% (85/208)  
.17 In this study the reduction in serum uric acid levels reached 
target 13% (3/23) for herbal exctract group and 33% (7/21) for 
allopurinol group (100 mg/day). 
 
Effects of herbal extracts and allopurinol on urinary 
uric acid levels  
The excretion of uric acid in this study was seen that the two 
groups did not difference. If compared to uric acid excretion at 
week 0 and week 4, allopurinol decreased uric acid excretion 
significantly (p = 0.037) with a decrease in uric acid level of urine 
24.3 ± 44.11 mg/dl. Previous studies (doses of 2000 mg  
/ day) found a significant increase in the second week (from 
week 1 (114.11 ± 745.74 mg/day), but after 4 weeks there were 
no significant differences.4  
In another study in patients with hyperuricemia who received 
allopurinol 300 mg for 6 months, there was a decrease in 
excretion of uric acid levels as much as 36.4%, but decreased 
slightly when compared with febuxostat 80 mg for 6 months 
which decreased by 58,6% .18  
Apium graveolens has uricosuric and diuretic effect. In this 
study there was no examination of 24-hour urine and only 
using randomized urine, so diuretic effect of Apium 
graveolens cannot be evaluated, and the synergistic diuretic 
and uricosuric effects can be considered as reasons for not 
increasing uric acid levels in the herbal extract treatment 
group, as well as the effect of xantin oxidase inhibitors that 
can reduce overproduction of serum uric acid . 
 
Effects of herbal extracts and allopurinol on hsCRP 
levels Changes in hsCRP levels at week 4 and week 0 in the 
two groups showed no significant difference, but the herbal 
extract treatment group experienced a decrease in hsCRP 
level week 4 from week 0 (0.08 ± 0.639 mg/dl) compared the 
allopurinol group increased (0.33 ± 0.806 mg/dl).
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A study with subject obese postmenopausal women 
(BMI>  
30 kg/m2) received a calorie retention diet and 
Nigella sativa oil 3 grams/day for 8 weeks. Decrease 
in hsCRP level in the group that received Nigella 
sativa oil more than the group that only received a 
calorie retention diet (-54.5% compared to -21.4%, 
with p = 0.01) .19  
The administration of allopurinol in patients with 
hyperuricemia with type II DM has been reported to 
have the effect of reducing hsCRP levels. 
Allopurinol at a dose of 300 mg for 3 years has been 
shown to reduce hsCRP levels when compared with 
the control group (0.16 ± 0.07 mg/dl and 0.35  
± 0.18, with p <0.001) 20  
Allopurinol in patients with hyperuricemia associated 
endothelial function with hsCRP as a marker is as done 
by Kanbay et.al (2011). The subjects of this study were 
hyperuricemia patients who were treated with 
allopurinol 300 mg/day for 16 weeks compared to 
placebo and subjects with normal uric acid levels. In 
patients with hyperuricemia who received therapy 
there was a greater decrease in hsCRP (7.4  
± 5.8 mg/dl to 4.6 ± 3.7 mg/dl, p = 0.003) compared 
with placebo (6.9 ± 3.4 mg/dl to 5.9 ± 3.8 mg/dl, p 
= 0.04), but it has not been as low as hsCRP level in 
patients who do not have hyperuricemia (3.4 ± 2.2 
mg/dl) .21  
Some of the studies above were carried out with a 
duration of 8 weeks of intervention on the use of 
Nigella sativa with a dose of (human) use of 3000 
mg/day. Allopurinol in the above study was intervened 
for a minimum of 16 weeks at a dose of  
300 mg/day. 
 
Research Limitations 
Some limitations of this study include: intervention 
duration of 4 weeks, examination of uric acid 
excretion is measured using random urine, lipid 
profiles (HDL, LDL and triglycerides) were not 
examined and no assessment of glycemic status in 
patients with type II DM. 
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